The Journal of Thoracic and Cardiovascular Surgery
Volume 133, Issue 5 , Pages 1179-1185 , May 2007

Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non–small cell lung cancer

Received 6 August 2006 ,Revised 21 November 2006 ,Accepted 12 December 2006.

References 

  1. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–680
  2. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–158
  3. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–1892
  4. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol. 1998;16:622–634
  5. Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 1997;15:712–722
  6. Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R, et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy (A Southwest Oncology Group trial). J Thorac Cardiovasc Surg. 1993;105:97–106
  7. Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non–small cell lung cancer. Ann Oncol. 2005;16:1069–1075
  8. Machtay M, Lee JH, Stevenson JP, Shrager JB, Algazy KM, Treat J, et al. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non–small cell lung carcinoma: long-term results and associations with pathologic response. J Thorac Cardiovasc Surg. 2004;127:108–113
  9. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. Taxanes as first-line therapy for advanced non–small cell lung cancer: a systematic review and practice guideline. Lung Cancer. 2005;50:355–374
  10. Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg. 2004;78:1200–1206
  11. Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non–small cell lung cancer: outcomes update of North American Intergroup 0139 (RTOG 9309). Proc Am Soc Clin Oncol. 2005;23(16S Part 1):624s
  12. Rami-Porta R, Mateu-Navarro M, Serra-Mitjans M, Hernandez-Rodriguez H. Remediastinoscopy: comments and updated results. Lung Cancer. 2003;42:363–364
  13. Pass HI. Mediastinal staging 2005: pictures, scopes, and scalpels. Semin Oncol. 2005;32:269–278
  14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. European Organization for Research and Treatment of Cancer National Cancer Institute of the United States National Cancer Institute of Canada New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216
  15. Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RT, Reznek RH. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol. 2000;73:1178–1184
  16. Yamamoto Y, Nishiyama Y, Monden T, Sasakawa Y, Ohkawa M, Gotoh M, et al. Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non–small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33:140–147
  17. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non–small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 2002;35:179–187
  18. Kaplan KS, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:45–81
  19. Byhardt RW, Martin L, Pajak TF, Shin KH, Emami B, Cox JD. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non–small cell lung cancer (NSCLC)—analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys. 1993;27:537–544
  20. The Japan Lung Cancer Society. In: Rule for clinical and pathological record of lung cancer. 6th ed.. Tokyo: Kanehara; 2003;p. 168–169editor
  21. Faber LP, Kittle CF, Warren WH, Bonomi PD, Taylor SG, Reddy S, et al. Preoperative chemotherapy and irradiation for stage III non–small cell lung cancer. Ann Thorac Surg. 1989;47:669–677
  22. Le Chevalier T, Arriagada R, Tarayre M, Lacombe-Terrier MJ, Laplanche A, Quoix E, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst. 1992;84:58
  23. Sause W, Kolesar P, Taylor SI, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable non–small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–364
  24. Arriagada R, Le Chevalier T, Quoix E, Ruffie P, de Cremoux H, Douillard JY, et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non–small cell lung carcinoma: a randomized study of 353 patients (GETCB (Groupe d’Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists). Int J Radiat Oncol Biol Phys. 1991;20:1183–1190
  25. Albain KS, Scott CB, Rusch V, Turrisi A, Shepherd FA, Smith C, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non–small cell lung cancer: Initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol. 2003;22:621;(abstr)
  26. Fowler WC, Langer CJ, Curran WJ, Keller SM. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg. 1993;55:986–989
  27. Mountain CF. A new international staging system for lung cancer. Chest. 1986;89:225S–233S
  28. Grunenwald DH, Albain KS. The potential role of surgery after induction treatment. Semin Radiat Oncol. 2004;14:335–339

PII: S0022-5223(07)00118-3

doi: 10.1016/j.jtcvs.2006.12.039

The Journal of Thoracic and Cardiovascular Surgery
Volume 133, Issue 5 , Pages 1179-1185 , May 2007

Article Tools

* Image Usage & Resolution